Skip to content
Screener

Medpace Holdings, Inc. MEDP Net Change in Cash

Net Change in Cash at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$817M+89.6%
Labcorp Holdings logo
Labcorp HoldingsLH
-$839.3M
IQVIA logo
IQVIAIQV
-$38M-113%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$27.1M-60.4%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$10.73M+207%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$228K

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.41B+35.7%
Enterprise value$16.05B+31.6%
P/E33.4×+4.5×
P/S5.9×+0.5×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026.

Filed
Apr 23, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001668397-26-000019
(Amounts in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Repurchases of common stock(371,900)
Net cash provided by (used in) financing activities12,670(345,966)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH(2,078)2,117
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH155,632(228,000)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period497,049669,436
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period$652,681$441,436
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION —
Share repurchases—non-cash$22,343

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s net change in cash?
Medpace Holdings, Inc. (MEDP) reported net change in cash of $155.63M in Q1 2026.
How has Medpace Holdings, Inc.'s net change in cash changed year-over-year?
Medpace Holdings, Inc.'s net change in cash increased by 168.3% year-over-year, from -$228M to $155.63M.
What is the long-term trend for Medpace Holdings, Inc.'s net change in cash?
Over 3 years (2021 to 2024), Medpace Holdings, Inc.'s net change in cash has grown at a 32.2% compound annual growth rate (CAGR), from $183.54M to $423.99M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Medpace Holdings, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude